Publicação
Breakthrough Technologies Drive Upsurge in CNS Dealmaking
IQVIA Pharma Deals
Sep 09, 2022

In recent years, diseases of the central nervous system (CNS) have increasingly become more prominent in dealmaking within the life sciences sector, despite the multiple challenges faced in drug development such as high R&D costs and late-stage clinical disappointments. Notably, there was a marked increase in CNS deal volume from 2020 to 2021, with neurology drug candidates being the key drivers of several high-profile deals, particularly in relation to novel therapeutic modalities and delivery approaches.

Related solutions

Contact Us